AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00765557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study NCT01642979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole+cyclosporin A+Glucocorticoids
Description: Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
Study NCT01642979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A+Glucocorticoids
Description: cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
Study NCT01642979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Glucocorticoids 0.5-1mg/kg every day(prednisone)
Study NCT01191918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and Lithium
Description: Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
Study NCT01191918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Lithium
Study NCT01655797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia
Description: Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
Study NCT04188587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-I&T
Description: All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
Study NCT01058655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT01058655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC
Study NCT04856436 — intervention group
Intervention type: DRUG
Intervention: Benzodiazepine
Description: Exposure to benzodiazepine during early pregnancy
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
Study NCT02154074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: the same volume of saline + Isoflurane during operation
Study NCT02544646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Changes in Ocular rigidity
Description: measured before the operation and 28±7 days after the operation
Study NCT03917238 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: gallium-68-exendin injection followed by PET/CT scan
Description: After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
Study NCT02733094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Study NCT04185779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Diagnostic colonoscopy
Study NCT04110145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
Study NCT04110145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
Study NCT03195764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1101 (Tosylate)
Description: T-1101 (Tosylate) powder in bottle
Study NCT01827956 — intervention group
Intervention type: OTHER
Intervention: Blood sample for identifying the polymorphism
Description: Blood sample for identifying the polymorphism
Study NCT04342377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Selective Targeted Sampling
Description: Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
Study NCT04342377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Sampling
Description: All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
Study NCT01258348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: LY573636-sodium
Description: Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression.
Study NCT02741050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Intervention
Description: The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
Study NCT02741050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
Study NCT02839291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionaries
Study NCT02839291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous or oral bone antiresorptive treatments
Study NCT04214990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily aspirin 100 mg for 5 years
Study NCT04214990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily placebo for 5 years
Study NCT01258348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression.
Study NCT02144532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short-sleeved vest CICATREX SED®)
Description: Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
Study NCT00444223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorine F 18 FEQA + positron emission tomography
Study NCT01412645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months
Study NCT01412645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months
Study NCT02216253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract
Description: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
Study NCT02216253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice a day 7 days before and after surgery
Study NCT00316303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: This vaccine will be given in three parts: at entry and after 3 and 6 months.
Study NCT00316303 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
Study NCT01434472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
Study NCT01434472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT02992613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty with ultra-congruent (UC) insert
Study NCT05820373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
Study NCT05820373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
Study NCT05820373 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive control group
Description: The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
Study NCT03530527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with biliary stenting
Description: ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
Study NCT03530527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided biliary drainage
Description: EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
Study NCT02740439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado
Description: The intervention meals will contain 1 large avocado.
Study NCT02740439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control meals will be isocaloric to the intervention meals but will not contain avocado.
Study NCT00933829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Suture Arm
Description: use of irradiated polyglactin 910
Study NCT00933829 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-absorbable suture (Prolene)
Description: suture
Study NCT00933829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: non-absorable sutures and absorable sutures
Study NCT00933829 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: suture
Description: non-absorable sutures and absorable sutures
Study NCT01395667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
Study NCT04351854 — intervention group
Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
Study NCT04043767 — intervention group
Intervention type: PROCEDURE
Intervention: Measurements of thyromental distances, hyomental distances and neck circumferences
Description: thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
Study NCT02772315 — intervention group
Intervention type: OTHER
Intervention: omics
Description: diagnostic procedures applying omics results
Study NCT00646451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin (Lyrica)
Description: 75 mg bid to 300 mg bid based on per subject tolerability
Study NCT00646451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to 4 capsules bid as tolerated
Study NCT01510912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 35 mg bid or tid Capsules
Study NCT03745118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EpiTel EpiLog
Description: Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
Study NCT01434472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01434472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indium In-111 Ibritumomab Tiuxetan
Description: Given IV
Study NCT01434472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01434472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01434472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV prior to yttrium Y 90 ibritumomab tiuxetan
Study NCT01434472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01434472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y-90 Ibritumomab Tiuxetan
Description: Given IV
Study NCT01434472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT01401816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
Study NCT04567966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split-block technique
Description: Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
Study NCT04567966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortico-cancellous block graft
Description: Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
Study NCT01240044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal rebalancing
Description: In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
Study NCT01240044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
Study NCT02992613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with posterior-stabilized (PS) insert
Study NCT01530308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: An oral dosage of 1mg twice daily at 12am and 8pm.
Study NCT02002442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
Study NCT02002442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash
Description: An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
Study NCT02656992 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training group
Study NCT02656992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training group
Study NCT01530308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral dosage of 1mg twice-daily at 12am and 8 pm.
Study NCT04661488 — intervention group
Intervention type: DEVICE
Intervention: AI driven triage-system
Description: AI driven triage-system
Study NCT02918331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg)
Description: Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
Study NCT02918331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
Study NCT02918331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
Study NCT03398018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repository corticotropin injection
Description: 80 units twice per week as a subcutaneous injection